Our Team

Meet the leaders changing drug discovery

Guido Lanza
CEO
Guido Lanza is the President and CEO of Numerate. Formerly, Guido was the co-founder and Chief Technical Officer of Pharmix, where he served on the company’s Board of Directors for Read More
Brandon Allgood
CTO
Brandon Allgood manages the development and application of Numerate’s AI platform and is responsible for Numerate’s technological vision. Brandon has also served as Director of Computational Science at Numerate and Read More
John Griffin
CSO
John Griffin is responsible for Numerate’s therapeutic programs and collaborations. He was formerly co-founder and Chief Scientific Officer of Theravance, Inc., a publicly traded biopharmaceutical company. A former Assistant Professor Read More
Uwe Klein
VP, Biology
Uwe Klein is responsible for all aspects of Numerate’s experimental biology strategy. He has over 19 years of experience in drug discovery, coming from Theravance Biopharma, where he last held the Read More